Company Profile
Venus Medtech (Hangzhou) provides the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and globally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe
VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product.
Its portfolio also includes Venus-PowerX, a self-expanding dry-tissue product, Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation, and renal artery denervation ablation system for the treatment of hypertension
Procedural accessories comprising catheter sheath product and balloon catheter. Incorporated in 2009, Venus Medtech (Hangzhou) is headquartered in Hangzhou, the People's Republic of China.